{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?uin=195639", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?uin=195639", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?uin=195639&_metadata=all", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&uin=195639", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?uin=195639", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?uin=195639", "items" : [{"_about" : "http://data.parliament.uk/resources/1655804", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1655804/answer", "answerText" : {"_value" : "<p>Through the Vaccine Taskforce, over £405 million was invested in the United Kingdom\u2019s vaccine manufacturing capabilities across several modalities, to ensure a robust response to COVID-19 and future health emergencies. In December 2022 the Government signed a ten-year strategic partnership with Moderna which will have the capacity to produce up to 250 million cutting-edge mRNA vaccines per year onshore in the event of a pandemic. In May this year, the Government announced a Biomanufacturing Fund, worth up to £38 million, to incentivise investment in commercial-scale vaccines and biotherapeutics manufacturing.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
        }
        , "answeringMemberConstituency" : {"_value" : "Lewes"}
        , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
        , "dateOfAnswer" : {"_value" : "2023-09-08", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-09-08T14:13:16.69Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-09-01", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Vaccination: Manufacturing Industries"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to his Department\u2019s paper A review of the Vaccine Taskforce, published on 29 August 2023, what funds the Office for Life Sciences has to invest in additional vaccine production capacity in the UK in order to achieve the onshoring programme objective set for the Vaccines Taskforce.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/318", "label" : {"_value" : "Biography information for John Spellar"}
      }
      , "tablingMemberConstituency" : {"_value" : "Warley"}
      , "tablingMemberPrinted" : [{"_value" : "John Spellar"}
      ], "uin" : "195639"}
    , {"_about" : "http://data.parliament.uk/resources/1015095", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1015095/answer", "answerText" : {"_value" : "<p>The information requested is not readily available and to provide it would incur disproportionate cost.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4071", "label" : {"_value" : "Biography information for Sarah Newton"}
        }
        , "answeringMemberConstituency" : {"_value" : "Truro and Falmouth"}
        , "answeringMemberPrinted" : {"_value" : "Sarah Newton"}
        , "dateOfAnswer" : {"_value" : "2018-11-29", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "195640"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-29T13:19:08.743Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "29"}
      , "answeringDeptShortName" : {"_value" : "Work and Pensions"}
      , "answeringDeptSortName" : {"_value" : "Work and Pensions"}
      , "date" : {"_value" : "2018-11-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Personal Independence Payment: Appeals"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Work and Pensions, what proportion of personal independence payment cases overturned at (a) reconsideration and (b) appeal stage were initially assessed as scoring zero points in (i) Glasgow South West constituency, (ii) Scotland and (iii) the UK in each of the last three years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4463", "label" : {"_value" : "Biography information for Chris Stephens"}
      }
      , "tablingMemberConstituency" : {"_value" : "Glasgow South West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Stephens"}
      ], "uin" : "195639"}
    , {"_about" : "http://data.parliament.uk/resources/47333", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/47333/answer", "answerText" : {"_value" : "<p /> <p /> <p>The responsibility for the oversight of work-based pensions in the UK rests with the Pensions Regulator which was set up under the Pensions Act 2004. Parliament gave the Pensions Regulator operational independence, which means that Ministers are not involved in decisions to exercise its powers or able to intervene in its casework. It would therefore not be appropriate for Ministers to comment on any individual pension scheme. Where it appears that scheme abandonment has taken place, it is a matter for the Regulator to establish whether the legal tests in relation to its \u2018anti-avoidance' powers, including the power to issue contribution notices, are met.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/220", "label" : {"_value" : "Biography information for Steve Webb"}
        }
        , "answeringMemberConstituency" : {"_value" : "Thornbury and Yate"}
        , "answeringMemberPrinted" : {"_value" : "Steve Webb"}
        , "dateOfAnswer" : {"_value" : "2014-04-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-04-10T12:00:00.00Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "29"}
      , "answeringDeptShortName" : {"_value" : "Work and Pensions"}
      , "answeringDeptSortName" : {"_value" : "Work and Pensions"}
      , "date" : {"_value" : "2014-04-07", "_datatype" : "dateTime"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Work and Pensions, what discussions the Government has had with the government of Russia on the failure of certain Russian companies to fulfil their obligations in relation to pension payments to UK citizens following those companies acquiring the assets of UK businesses.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4243", "label" : {"_value" : "Biography information for Dan Jarvis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Barnsley Central"}
      , "tablingMemberPrinted" : [{"_value" : "Dan Jarvis"}
      ], "uin" : "195639"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}